"PROTINUS" (lat. forward, further") is the name of the project with which the biopharmaceutical company CSL Behring will significantly increase the production capacity of immunoglobulin at its site.
Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
CSL Behring shuts down filling department, lays off 65 staffers at major Illinois manufacturing site
At a large plant south of Chicago in Illinois, CSL Behring is shutting down one of its filling departments and letting go of 65 employees. The staffers at what CSL has called its “leading-edge ...
(The Center Square) – A global biopharmaceutical company has announced it will invest $1.5 billion for a new manufacturing facility in Bradley, but the taxpayer cost of the project is unknown. On ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results